Denosumab, osteoporosis, and prevention of fractures.
Kiechl
Stefan
S
Willeit
Johann
J
Schett
Georg
G
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069448:Denosumab; D005260:Female; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced* / Q000401:mortality; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D053244:Osteoprotegerin / Q000097:blood; D053245:RANK Ligand / Q000009:adverse effects* / Q000037:antagonists & inhibitors* / Q000097:blood / Q000627:therapeutic use; D016103:Spinal Fractures / Q000517:prevention & control
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D053244:Osteoprotegerin; D053245:RANK Ligand; C505688:TNFSF11 protein, human; D000069448:Denosumab